<?xml version="1.0" encoding="UTF-8"?>
<p>Currently, it was suggested to collect whole blood or plasma from recovery patients for transfusion to the progressive rapidly, severe and critical COVID‐19 patients during the SARS‐COV‐2 outbreak, but the following principles should be followed: (a) the patient's disease course should not exceed 3 weeks or has viraemia and (b) patients with rapid progression and early severity should be evaluated comprehensively by clinical experts.
 <xref rid="jcmm15364-bib-0100" ref-type="ref">
  <sup>100</sup>
 </xref> A recent study showed that conditions of five COVID‐19 patients have been improved after treating with the plasma of the rehabilitated patients.
 <xref rid="jcmm15364-bib-0101" ref-type="ref">
  <sup>101</sup>
 </xref> Two of these antibodies were tested and showed strong anti‐SARS‐CoV‐2 capabilities by the reduction of the binding of SARS‐CoV‐2 S protein RBD to human ACE2 with reduction rate of 99.2% and 98.5%, respectively.
 <xref rid="jcmm15364-bib-0102" ref-type="ref">
  <sup>102</sup>
 </xref> However, more clinical research should be conducted to prove the safety and effectiveness of convalescent plasma therapy among COVID‐19 patients.
 <xref rid="jcmm15364-bib-0103" ref-type="ref">
  <sup>103</sup>
 </xref>
</p>
